Author: Shuya Lu; Qi Zhou; Liping Huang; Qianling Shi; Siya Zhao; Zijun Wang; Weiguo Li; Yuyi Tang; Yanfang Ma; Xufei Luo; Toshio Fukuoka; Hyeong Sik Ahn; Myeong Soo Lee; Zhengxiu Luo; Enmei Liu; Yaolong Chen; Chenyan Zhou; Donghong Peng
Title: Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis Document date: 2020_4_22
ID: 935r7w01_51
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 fever, but not the risk of death and lung inflammation absorption in patients with COVID-19 or SARS. In addition, glucocorticoid therapy may even prolong the duration of hospitalization. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as infections and osteonecrosis. We found moderate-quality ev.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 fever, but not the risk of death and lung inflammation absorption in patients with COVID-19 or SARS. In addition, glucocorticoid therapy may even prolong the duration of hospitalization. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as infections and osteonecrosis. We found moderate-quality evidence that in patients with mild SARS glucocorticoids may be associated with a more than three-fold increase in the risk of death.
Search related documents:
Co phrase search for related documents- adverse reaction and fold increase: 1, 2
- adverse reaction and high dose: 1, 2, 3, 4, 5, 6, 7, 8
- adverse reaction and hospitalization duration: 1
- adverse reaction and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse reaction and lung inflammation: 1
- adverse reaction and moderate quality: 1
- adverse reaction and SARS patient: 1
- death risk and fold increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- death risk and glucocorticoid therapy: 1, 2, 3, 4, 5, 6, 7
- death risk and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- death risk and hospitalization duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- death risk and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- death risk and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
- death risk and moderate quality: 1, 2
- death risk and moderate quality evidence: 1, 2
- death risk and SARS patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- death risk fold increase and fold increase: 1, 2, 3, 4, 5, 6, 7, 8, 9
- fold increase and high dose: 1, 2, 3
- fold increase and hospitalization duration: 1
Co phrase search for related documents, hyperlinks ordered by date